PEG-Endostar (pegylated recombinant human endostatin) / Simcere - LARVOL DELTA

Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases (ACR Convergence 2025) - "Taken together, SIM0710 shows broad functional inhibition in diverse pathogenic immune cells and may offer potential therapeutic benefit for treating multiple autoimmune diseases."

Graft versus Host Disease • Immunology • Inflammation • Inflammatory Arthritis • BTLA • CD34 • IFNA1 • IL6

Discovery and characterization of SIM0710 a novel BTLA agonist antibody for autoimmune/Inflammatory disease (IMMUNOLOGY 2025) - "Notably, SIM0710 also significantly reduced the anti-dsDNA IgG level in the serum of an IMQ induced SLE model in hu-CD34 HSC NOG-EXL mice. Taken together, SIM0710 shows broad functional inhibition on pathogenic immune cells and may offer potential therapeutic benefit for treating multiple autoimmune diseases.Keywords: Animals Rodent; Cells B Cells Dendritic Cells T Cells; Diseases Autoimmunity"

Graft versus Host Disease • Immunology • Inflammation • Inflammatory Arthritis • BTLA • CD34 • IFNA1 • IL6 • TLR7

Preclinical data of four innovative autoimmune drugs from Innovent will be published in 2025AAI [Google translation] (Simcere Press Release) - "SIM0710 developed by Innovent is a new BTLA agonist monoclonal antibody that effectively inhibits the proliferation of human primary B cells and T cells in in vitro experiments, and simultaneously reduces IL-6 and multiple Th cytokines. It can also regulate the function of human primary dendritic cells (DC) and inhibit the expression of multiple co-stimulatory proteins. In in vivo experiments, SIM0710 significantly prolonged the overall survival of the humanized GvHD mouse model and significantly reduced immune indicators such as serum anti-dsDNA IgG levels in the humanized SLE model. This molecule has the potential to become an innovative therapy for the treatment of a variety of autoimmune diseases."

Preclinical • Systemic Lupus Erythematosus

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer